SEC Form SC 13G filed by Apogee Therapeutics Inc.

10/4/24 10:05:58 AM ET

$APGE

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $APGE alert in real time by email

SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. _ )^*

Apogee Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

03770N101

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X]	Rule 13d-1(b)
[ ]	Rule 13d-1(c)
[ ]	Rule 13d-1(d)

^* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)

CUSIP No.

03770N101

1.	NAMES OF REPORTING PERSONS Wellington Management Group LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	4,509,598
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	4,814,400
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,814,400
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.70%
12.	TYPE OF REPORTING PERSON HC

CUSIP No.

03770N101

1.	NAMES OF REPORTING PERSONS Wellington Group Holdings LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	4,509,598
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	4,814,400
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,814,400
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.70%
12.	TYPE OF REPORTING PERSON HC

CUSIP No.

03770N101

1.	NAMES OF REPORTING PERSONS Wellington Investment Advisors Holdings LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	4,509,598
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	4,814,400
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,814,400
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.70%
12.	TYPE OF REPORTING PERSON HC

CUSIP No.

03770N101

1.	NAMES OF REPORTING PERSONS Wellington Management Company LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	4,505,288
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	4,699,376
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,699,376
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.44%
12.	TYPE OF REPORTING PERSON IA

Item 1.
	(a)	Name of Issuer Apogee Therapeutics, Inc.
	(b)	Address of Issuer's Principal Executive Offices 221 Crescent St Building 17, Suite 102B Waltham, MA 02453
Item 2.
	(a)	Name of Person Filing Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP
	(b)	Address of Principal Business Office or, if None, Residence c/o Wellington Management Company LLP 280 Congress Street Boston, MA 02210
	(c)	Citizenship Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware
	(d)	Title of Class of Securities Common Stock
	(e)	CUSIP Number 03770N101
Item 3.	If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
	(a)	[ ]	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
	(b)	[ ]	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)	[ ]	Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)	[ ]	Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
	(e)	[X]	An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E); *
	(f)	[ ]	An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
	(g)	[X]	A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
	(h)	[ ]	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	[ ]	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j)	[ ]	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
		If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
	Wellington Management Group LLP - HC Wellington Group Holdings LLP - HC Wellington Investment Advisors Holdings LLP - HC Wellington Management Company LLP - IA
Item 4.	Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
	(a)	Amount Beneficially Owned:
		See the responses to Item 9 on the attached cover pages.
	(b)	Percent of Class:
		See the responses to Item 11 on the attached cover pages.
	(c)	Number of shares as to which such person has:
		(i)	sole power to vote or to direct the vote	0
		(ii)	shared power to vote or to direct the vote	See the responses to Item 6 on the attached cover pages.
		(iii)	sole power to dispose or to direct the disposition of	0
		(iv)	shared power to dispose or to direct the disposition of	See the responses to Item 8 on the attached cover pages.
Item 5.	Ownership of Five Percent or Less of Class.
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
	The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
	Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.
	Wellington Group Holdings LLP – HC
	Wellington Investment Advisors LLP – HC
	Wellington Management Global Holdings, Ltd. - HC
	One or more of the following investment advisers (the “Wellington Investment Advisers”):
	Wellington Management Company LLP – IA
	Wellington Management Canada LLC – IA
	Wellington Management Singapore Pte Ltd – IA
	Wellington Management Hong Kong Ltd – IA
	Wellington Management International Ltd – IA
	Wellington Management Japan Pte Ltd – IA
	Wellington Management Australia Pty Ltd - IA
	The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
Item 8.	Identification and Classification of Members of the Group. Not Applicable.
Item 9.	Notice of Dissolution of Group. Not Applicable.
Item 10.	Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	By: Wellington Management Group LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: October 7,2024

	By: Wellington Group Holdings LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: October 7,2024

	By: Wellington Investment Advisors Holdings LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: October 7,2024

	By: Wellington Management Company LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: October 7,2024

Get the next $APGE alert in real time by email

Recent Analyst Ratings for

$APGE

Date	Price Target	Rating	Analyst
7/7/2025	$100.00 → $115.00	Buy	BTIG Research
3/13/2025	$95.00	Buy	Citigroup
11/25/2024	$89.00	Buy	Canaccord Genuity
5/10/2024	$80.00	Buy	BofA Securities
12/20/2023	$43.00	Buy	BTIG Research
8/8/2023		Outperform	TD Cowen
8/8/2023	$40.00	Outperform	Wedbush
8/8/2023	$29.00	Buy	Guggenheim

More analyst ratings

SEC Form SC 13G filed by Apogee Therapeutics Inc.

10/4/24 10:05:58 AM ET

$APGE

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $APGE alert in real time by email

SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. _ )^*

Apogee Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

03770N101

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X]	Rule 13d-1(b)
[ ]	Rule 13d-1(c)
[ ]	Rule 13d-1(d)

CUSIP No.

03770N101

1.	NAMES OF REPORTING PERSONS Wellington Management Group LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	4,509,598
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	4,814,400
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,814,400
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.70%
12.	TYPE OF REPORTING PERSON HC

CUSIP No.

03770N101

1.	NAMES OF REPORTING PERSONS Wellington Group Holdings LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	4,509,598
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	4,814,400
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,814,400
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.70%
12.	TYPE OF REPORTING PERSON HC

CUSIP No.

03770N101

1.	NAMES OF REPORTING PERSONS Wellington Investment Advisors Holdings LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	4,509,598
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	4,814,400
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,814,400
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.70%
12.	TYPE OF REPORTING PERSON HC

CUSIP No.

03770N101

1.	NAMES OF REPORTING PERSONS Wellington Management Company LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	4,505,288
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	4,699,376
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,699,376
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.44%
12.	TYPE OF REPORTING PERSON IA

Item 1.
	(a)	Name of Issuer Apogee Therapeutics, Inc.
	(b)	Address of Issuer's Principal Executive Offices 221 Crescent St Building 17, Suite 102B Waltham, MA 02453
Item 2.
	(a)	Name of Person Filing Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP
	(b)	Address of Principal Business Office or, if None, Residence c/o Wellington Management Company LLP 280 Congress Street Boston, MA 02210
	(c)	Citizenship Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware
	(d)	Title of Class of Securities Common Stock
	(e)	CUSIP Number 03770N101
Item 3.	If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
	(a)	[ ]	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
	(b)	[ ]	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)	[ ]	Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)	[ ]	Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
	(e)	[X]	An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E); *
	(f)	[ ]	An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
	(g)	[X]	A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
	(h)	[ ]	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	[ ]	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j)	[ ]	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
		If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
	Wellington Management Group LLP - HC Wellington Group Holdings LLP - HC Wellington Investment Advisors Holdings LLP - HC Wellington Management Company LLP - IA
Item 4.	Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
	(a)	Amount Beneficially Owned:
		See the responses to Item 9 on the attached cover pages.
	(b)	Percent of Class:
		See the responses to Item 11 on the attached cover pages.
	(c)	Number of shares as to which such person has:
		(i)	sole power to vote or to direct the vote	0
		(ii)	shared power to vote or to direct the vote	See the responses to Item 6 on the attached cover pages.
		(iii)	sole power to dispose or to direct the disposition of	0
		(iv)	shared power to dispose or to direct the disposition of	See the responses to Item 8 on the attached cover pages.
Item 5.	Ownership of Five Percent or Less of Class.
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
	The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
	Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.
	Wellington Group Holdings LLP – HC
	Wellington Investment Advisors LLP – HC
	Wellington Management Global Holdings, Ltd. - HC
	One or more of the following investment advisers (the “Wellington Investment Advisers”):
	Wellington Management Company LLP – IA
	Wellington Management Canada LLC – IA
	Wellington Management Singapore Pte Ltd – IA
	Wellington Management Hong Kong Ltd – IA
	Wellington Management International Ltd – IA
	Wellington Management Japan Pte Ltd – IA
	Wellington Management Australia Pty Ltd - IA
	The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
Item 8.	Identification and Classification of Members of the Group. Not Applicable.
Item 9.	Notice of Dissolution of Group. Not Applicable.
Item 10.	Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	By: Wellington Management Group LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: October 7,2024

	By: Wellington Group Holdings LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: October 7,2024

	By: Wellington Investment Advisors Holdings LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: October 7,2024

	By: Wellington Management Company LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: October 7,2024

Get the next $APGE alert in real time by email

Recent Analyst Ratings for

$APGE

Date	Price Target	Rating	Analyst
7/7/2025	$100.00 → $115.00	Buy	BTIG Research
3/13/2025	$95.00	Buy	Citigroup
11/25/2024	$89.00	Buy	Canaccord Genuity
5/10/2024	$80.00	Buy	BofA Securities
12/20/2023	$43.00	Buy	BTIG Research
8/8/2023		Outperform	TD Cowen
8/8/2023	$40.00	Outperform	Wedbush
8/8/2023	$29.00	Buy	Guggenheim

More analyst ratings

SEC Form SC 13G filed by Apogee Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. _ )*

SIGNATURE

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $APGE

SEC Form SC 13G filed by Apogee Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. _ )*

SIGNATURE

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $APGE

$APGE Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Mckenna Mark C. bought $990,775 worth of shares (20,000 units at $49.54) (SEC Form 4)

$APGE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Dambkowski Carl exercised 7,365 shares at a strike of $22.86 and sold $454,954 worth of shares (10,090 units at $45.09), decreasing direct ownership by 1% to 238,998 units (SEC Form 4)

SEC Form 4 filed by Director Fairmount Funds Management Llc

SEC Form 4 filed by Director Shah Nimish P

$APGE Press Releases

Fastest customizable press release news feed in the world

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

$APGE SEC Filings

Apogee Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.

SEC Form 10-Q filed by Apogee Therapeutics Inc.

$APGE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

BTIG Research reiterated coverage on Apogee Therapeutics with a new price target

Citigroup initiated coverage on Apogee Therapeutics with a new price target

Canaccord Genuity initiated coverage on Apogee Therapeutics with a new price target

$APGE Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.